Q-omics provides the consensus-scored HNRNPA3P11 profile across patient tissues and cancer cell-line models. HNRNPA3P11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, HNRNPA3P11 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, HNRNPA3P11 RNA expression shows 17,115 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where HNRNPA3P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA3P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA3P11 survival associations across molecular data types. HNRNPA3P11 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA3P11 RNA expression–survival associations across cancer types. High HNRNPA3P11 expression shows unfavorable associations in UVM, STAD, CHOL, MESO and ACC, but favorable associations in PRAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify UVM as the clearest survival context for HNRNPA3P11 RNA expression.
This table summarizes HNRNPA3P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA3P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA3P11 shows higher tumor expression in COAD, HNSC, LIHC, STAD, BRCA and UCEC. The COAD box plot shows higher HNRNPA3P11 RNA expression in tumor versus normal tissue (log2 FC = +0.307, t-test p < 0.001).
This table shows molecular features associated with HNRNPA3P11 in patient tissues and cancer cell lines. In patient samples, HNRNPA3P11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
